Oxaliplatin‑induced changes in splenic volume and liver fibrosis indices: retrospective analyses of colon cancer patients receiving adjuvant chemotherapy

• Published in: Journal of chemotherapy (Florence) 2024-05, Vol.36 (3), p.249-257
• Main Authors: Bir Yücel, Kadriye, Kilic, Atiye Cenay Karabörk, Sütcüoglu, Osman, Yazıcı, Ozan, Kilic, Koray, Savaş, Gözde, Uner, Aytug, Günel, Nazan, Özet, Ahmet, Özdemir, Nuriye
• Format: Article
• Language: English
• Subjects: Antineoplastic Combined Chemotherapy Protocols - adverse effects; Capecitabine - adverse effects; Chemotherapy, Adjuvant - adverse effects; Colonic Neoplasms - drug therapy; Colonic Neoplasms - pathology; Fluorouracil - adverse effects; Humans; Leucovorin - adverse effects; Liver Cirrhosis; Neoplasm Staging; Oxaliplatin - adverse effects; Retrospective Studies
• ISSN: 1120-009X; 1973-9478
• DOI: 10.1080/1120009X.2023.2246786

The aim of our study was to evaluate the association between increased splenic volume (SV) and liver fibrosis indices in colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy. Patients who received adjuvant oxaliplatin-based regimens with the diagnosis of stage II and III colon cancer were evaluated. Splenic volume measurements, liver function tests, platelet count, and non-invasive liver fibrosis indices [NAFLD fibrosis score (NFS), AST to platelet ratio (APRI), and Fibrosis-4 (FIB-4)] were measured before and after treatment. A 30% increase in SV after chemotherapy compared to baseline was considered increased SV. The rate of increase in SV was 57.7% in the whole group. An increase in SV was shown at a higher rate in patients treated with capecitabine and oxaliplatin (CAPOX) than those treated with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) (66.3% vs. 36.8%,  = 0.002). Furthermore, the CAPOX regimen (OR: 2.831, 95% CI: 1.125-7.121;  = 0.027), and higher post-treatment FIB-4 score (OR: 3.779; 95% CI:1.537- 9.294,  = 0.004) were determined as independent risk factors for the increased SV. Our study revealed that increased SV had a significant association with higher FIB-4 score in patients treated with oxaliplatin-based chemotherapy.